2-(4-(4-ethoxy-6-((4-methoxybenzyl)oxy)pyridin-3-yl)-2-fluorophenyl)-N-(3-(1, 1,1-trifluoro-2-methylpropan-2-yl)isoxazol-5-yl)acetamide → 2-(4-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorophenyl)-N-(3-(1, 1,1-trifluoro-2-methylpropan-2-yl)isoxazol-5-yl)acetamide

Participants

Reaction Conditions

Reaction Steps

A mixture of 2-(4-(4-ethoxy-6-((4-methoxybenzyl)oxy)pyridin-3-yl)-2-fluorophenyl)-N-(3-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-5-yl)acetamide (70 mg, 0.119 mmol) and TFA (10% in DCM, 50 mL) was stirred at 25° C. for 2 h. The mixture was concentrated. The crude material was purified by preparative HPLC (MeCN/H2O as eluants, basic condition) to give a white solid of 2-(4-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorophenyl)-N-(3-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-5-yl)acetamide (24.61 mg, 0.051 mmol, 43% yield): 1H NMR (400 MHz, CD3OD) δ 7.39-7.32 (m, 1H), 7.26-7.18 (m, 1H), 6.37 (s, 1H), 5.99 (s, 1H), 4.10 (q, J=6.8 Hz, 2H), 3.82 (s, 2H), 1.53 (s, 6H), 1.37 (t, J=7.2 Hz, 3H); ES-LCMS m/z: 468 (M+H).

Provenance & Evidence